188 related articles for article (PubMed ID: 29335712)
21. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study.
Bjørge T; Lie AK; Hovig E; Gislefoss RE; Hansen S; Jellum E; Langseth H; Nustad K; Tropé CG; Dørum A
Br J Cancer; 2004 Nov; 91(10):1829-34. PubMed ID: 15477862
[TBL] [Abstract][Full Text] [Related]
22. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis.
Chiang JW; Karlan BY; Cass L; Baldwin RL
Gynecol Oncol; 2006 Jun; 101(3):403-10. PubMed ID: 16360812
[TBL] [Abstract][Full Text] [Related]
23. Frequency of BRCA1 dysfunction in ovarian cancer.
Geisler JP; Hatterman-Zogg MA; Rathe JA; Buller RE
J Natl Cancer Inst; 2002 Jan; 94(1):61-7. PubMed ID: 11773283
[TBL] [Abstract][Full Text] [Related]
24. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma.
Ho CM; Lai HC; Huang SH; Chien TY; Lin MC; Chang SF
Eur J Clin Invest; 2010 Apr; 40(4):310-8. PubMed ID: 20486992
[TBL] [Abstract][Full Text] [Related]
25. Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.
Wang C; Horiuchi A; Imai T; Ohira S; Itoh K; Nikaido T; Katsuyama Y; Konishi I
J Pathol; 2004 Feb; 202(2):215-23. PubMed ID: 14743504
[TBL] [Abstract][Full Text] [Related]
26. Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.
Shen YT; Wang L; Evans JC; Allen C; Piquette-Miller M
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31117198
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic inactivation of BRCA1 through promoter hypermethylation in ovarian cancer progression.
Wang YQ; Yan Q; Zhang JR; Li SD; Yang YX; Wan XP
J Obstet Gynaecol Res; 2013 Feb; 39(2):549-54. PubMed ID: 23006047
[TBL] [Abstract][Full Text] [Related]
28. Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?
Vineyard MA; Daniels MS; Urbauer DL; Deavers MT; Sun CC; Boerwinkle E; Bodurka DC; Gershenson DM; Crawford J; Lu KH
Gynecol Oncol; 2011 Feb; 120(2):229-32. PubMed ID: 21126756
[TBL] [Abstract][Full Text] [Related]
29. DNA hypomethylation-mediated activation of Cancer/Testis Antigen 45 (CT45) genes is associated with disease progression and reduced survival in epithelial ovarian cancer.
Zhang W; Barger CJ; Link PA; Mhawech-Fauceglia P; Miller A; Akers SN; Odunsi K; Karpf AR
Epigenetics; 2015; 10(8):736-48. PubMed ID: 26098711
[TBL] [Abstract][Full Text] [Related]
30. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women.
Rathi A; Virmani AK; Schorge JO; Elias KJ; Maruyama R; Minna JD; Mok SC; Girard L; Fishman DA; Gazdar AF
Clin Cancer Res; 2002 Nov; 8(11):3324-31. PubMed ID: 12429618
[TBL] [Abstract][Full Text] [Related]
31. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.
Chan KY; Ozçelik H; Cheung AN; Ngan HY; Khoo US
Cancer Res; 2002 Jul; 62(14):4151-6. PubMed ID: 12124354
[TBL] [Abstract][Full Text] [Related]
33. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1.
Rubin SC; Benjamin I; Behbakht K; Takahashi H; Morgan MA; LiVolsi VA; Berchuck A; Muto MG; Garber JE; Weber BL; Lynch HT; Boyd J
N Engl J Med; 1996 Nov; 335(19):1413-6. PubMed ID: 8875917
[TBL] [Abstract][Full Text] [Related]
34. A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
Vos S; van Diest PJ; Moelans CB
Crit Rev Oncol Hematol; 2018 Jul; 127():29-41. PubMed ID: 29891109
[TBL] [Abstract][Full Text] [Related]
35. DNA methylation of the immediate upstream region of BRCA1 major transcription start sites is an independent favorable prognostic factor in patients with high-grade serous ovarian cancer.
Ebata T; Yamashita S; Takeshima H; Yoshida H; Kawata Y; Kino N; Yasugi T; Terao Y; Yonemori K; Kato T; Ushijima T
Gynecol Oncol; 2022 Dec; 167(3):513-518. PubMed ID: 36253303
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.
Tomar T; de Jong S; Alkema NG; Hoekman RL; Meersma GJ; Klip HG; van der Zee AG; Wisman GB
Genome Med; 2016 Oct; 8(1):107. PubMed ID: 27765068
[TBL] [Abstract][Full Text] [Related]
37. p16 gene alterations in human ovarian cancers: comparison between tissue and blood samples.
Bammidi LS; Neerukonda GN; Murthy S; Kanapuram RD
Int J Gynecol Cancer; 2012 May; 22(4):553-60. PubMed ID: 22344043
[TBL] [Abstract][Full Text] [Related]
38. Single CpG island methylation is not sufficient to maintain the silenced expression of CASPASE-8 apoptosis-related gene among women with epithelial ovarian cancer.
Braga Lda C; Silva LM; Ramos AP; Piedade JB; Vidigal PV; Traiman P; da Silva Filho AL
Biomed Pharmacother; 2014 Feb; 68(1):87-91. PubMed ID: 24412083
[TBL] [Abstract][Full Text] [Related]
39. Aberrant methylation of breast and ovarian cancer susceptibility gene 1 in chemosensitive human ovarian cancer cells does not involve the phosphatidylinositol 3'-kinase-Akt pathway.
Wang YQ; Zhang JR; Li SD; He YY; Yang YX; Liu XL; Wan XP
Cancer Sci; 2010 Jul; 101(7):1618-23. PubMed ID: 20487263
[TBL] [Abstract][Full Text] [Related]
40. Failure of BRCA1 dysfunction to alter ovarian cancer survival.
Buller RE; Shahin MS; Geisler JP; Zogg M; De Young BR; Davis CS
Clin Cancer Res; 2002 May; 8(5):1196-202. PubMed ID: 12006538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
